CTLA4 and metastatic melanoma: Tremelimumab (CP-675,206) is another monoclonal antibody against CTLA-4, which promotes important and durable tumor regressions in approximately 10% of metastatic melanoma patients; however, unlike ipilimumab, no significant changes in terms of survival were observed between patients treated with tremelimumab and those treated with chemotherapy [54].